Evotec's Restructuring Leads To Q1 Improved Revenues and Reduced Losses
This article was originally published in The Pink Sheet Daily
Executive SummaryGerman drug discovery service company expects to be profitable by 2012.
You may also be interested in...
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.